Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C6GL | ISIN: US29384C1080 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:55
8,350 US-Dollar
+2,71 % +0,220
1-Jahres-Chart
ENTRADA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ENTRADA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ENTRADA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEntrada Therapeutics, Inc.: Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors1
DiEntrada Therapeutics, Inc. - 8-K, Current Report5
MoEntrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)56BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired...
► Artikel lesen
MoH.C. Wainwright bekräftigt Kaufempfehlung für Entrada Therapeutics-Aktie1
MoH.C. Wainwright reaffirms Buy rating on Entrada Therapeutics stock-
ENTRADA THERAPEUTICS Aktie jetzt für 0€ handeln
28.05.Entrada Therapeutics startet DMD-Studie im dritten Quartal 20251
28.05.Entrada Therapeutics, Inc.: Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne ...138- Company on track to begin ELEVATE-45-201 in Q3 2025 - - Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 - BOSTON...
► Artikel lesen
08.05.Entrada Therapeutics, Inc. - 10-Q, Quarterly Report-
08.05.Entrada Therapeutics, Inc. - 8-K, Current Report5
01.05.Arvinas, Entrada cut staff; Merck builds US hub for Keytruda7
30.04.Entrada lays off 20% of staff weeks after having FDA hold lifted3
31.03.Entrada Therapeutics stock rating holds with $20 target1
25.03.Entrada Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
24.03.Oppenheimer maintains Entrada stock Outperform with $30 target2
24.03.Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK1
24.03.Roth/MKM maintains Buy on Entrada stock, $23 target2
24.03.Entrada Therapeutics begins Duchenne study in UK1
24.03.Entrada Therapeutics, Inc. - 8-K, Current Report1
24.03.Entrada Therapeutics, Inc.: Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular ...214- Company on track to initiate ELEVATE-45-201 study in Q3 2025 - - ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing - - ELEVATE-45 is the second of three novel exon...
► Artikel lesen
28.02.Oppenheimer maintains Entrada stock Outperform with $30 target1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1